Benjamin Hohl Sells 991 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 991 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $27.53, for a total transaction of $27,282.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $75,210.00.
• On Thursday, June 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.57, for a total transaction of $95,922.50.
• On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total transaction of $98,515.00.

Enliven Therapeutics Trading Down 6.0 %

Shares of NASDAQ ELVN opened at $23.22 on Monday. The firm has a market capitalization of $1.09 billion, a PE ratio of -12.03 and a beta of 1.10. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67. The firm’s 50-day moving average is $22.82 and its 200-day moving average is $19.68.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ELVN. Janus Henderson Group PLC boosted its stake in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the last quarter. Baker BROS. Advisors LP bought a new position in Enliven Therapeutics during the 1st quarter worth approximately $2,020,000. Bank of New York Mellon Corp boosted its stake in Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares during the last quarter. Blackstone Inc. bought a new position in Enliven Therapeutics during the 1st quarter worth approximately $443,000. Finally, Rhumbline Advisers boosted its stake in Enliven Therapeutics by 29.9% during the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after acquiring an additional 11,420 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

ELVN has been the topic of several research reports. Mizuho initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target on the stock. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.